TBPH compared with CAN: revenue, margins and what each company keeps, and the suppliers and customers both name

TBPHTheravance Biopharma, Inc.

Mkt capRevenueRevenue

CANCanaan Inc.

Mkt capRevenueRevenue

Compare

TBPHTheravance Biopharma, Inc.

CANCanaan Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TBPH

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▼−0.12%×0.02

May 7 '26±10.3%▲+0.47%×0.05

Q1 FY26±12.0%▲+1.30%×0.11

Q3 FY25±24.6%▲+22.68%×0.92

CAN1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Sep 8 '26±36.4%▼−10.22%×0.28

= impliedTBPH realized, solidCAN realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

TBPHTheravance Biopharma, Inc.

17.03▲+0.02%· post 17.04

Mkt cap$884.2MRevenue$21MQ2 FY26Revenue$107MFY25

CANCanaan Inc.

0.20▼−12.00%· post 0.20

ClosedOct 30 '26

Mkt cap$143.6MRevenue—Revenue—

Compare

ClosedOct 30 '26

TBPHTheravance Biopharma, Inc.

CANCanaan Inc.

17.03▲+0.02%post 17.04

Price

0.20▼−12.00%post 0.20

$884.2M

Mkt cap

$143.6M

Q2 FY26$21M

Revenue

—

FY25$107M

Revenue

—

TBPH17.03▲+0.02%vsCAN0.20▼−12.00%ClosedOct 30 '26